CoreMedic has entered into a strategic partnership with InnoRa to accelerate clinical development of its transcatheter mitral valve repair system ChordArt.
InnoRa contributes over 20 years of experience in the development of innovative cardiovascular devices and their translation into clinical trials to the partnership. The partnership also includes an undisclosed investment by InnoRa. Bruno Scheller (University of Saarland, Saarland, Germany), a renowned expert in interventional cardiology and co-founder of InnoRa will join the supervisory board of CoreMedic.
Josef Bogenschütz, CEO of Coremedic, stated: “We are thrilled to embark on our partnership with InnoRa. We are developing ChordArt to offer a superior catheter-based therapy solution for the large and growing population of patients suffering from degenerative mitral valve regurgitation. Under our new partnership, we will jointly deploy our complementary resources to accelerate clinical development of ChordArt.”
Jodi Akin, chairwoman of the Supervisory Board of CoreMedic, stated: “Professor Scheller is a globally renowned expert in interventional cardiology. This comes at the exciting inflection point of our first-in-human clinical trial in Europe. We are delighted that Professor Scheller will join the Supervisory Board of CoreMedic and contribute his outstanding scientific and clinical expertise to the company.”
